Halozyme Therapeutics, Inc. (HALO)

Halozyme Therapeutics, Inc. (HALO) is a healthcare company (biotechnology) based in the United States. The share price is $96.16, down 0.35% on the day, which values the company at $10.96B. Price as of 17 Nov 2026, 18:23 UTC, from Yahoo Finance.

Key facts

Share price
$96.16−0.35% today
Market value
$10.96B
P/E ratio
24.0×last 12 months
Forward P/E
9.1×
Funk Score
71/100
Against its own history
Above its usual priceusual price $83.15
200-week average
$57.8566% above
Sector
Healthcare

Figures as of . Prices from Yahoo Finance (may be delayed); statements from company filings with the SEC and Yahoo Finance. Estimates, not advice.

Halozyme Therapeutics, Inc. in more detail

HALO trades at 24.0× its last twelve months' earnings, 9.1× next year's expected earnings, 6.1× sales. Measured against its own history, the price is 16% above what its usual multiples would imply ($83.15) — above its usual price. It sits 66% above its 200-week average of $57.85.

Over the last five fiscal years Halozyme Therapeutics, Inc. has compounded revenue 39.2% a year, earnings per share 23.0% a year, free cash flow 46.5% a year. Its Funk Score is 71 out of 100 (financial strength 6.2, profitability 7.6, growth 10.0, value 4.5, each out of 10).

In its favour: Altman Z in the safe zone; Share count keeps falling.

5 of the superinvestors tracked here hold HALO, including Josef Lakonishok (0.3% of the portfolio), John Overdeck and David Siegel (founders) (0.3% of the portfolio), Ray Dalio (founder) (0.1% of the portfolio).

Superinvestors holding HALO

5 of the investors tracked here report a position in their latest 13F filing.

Compare

Health Care companies of similar size

Side by side:HALO vs DVA (Halozyme Therapeutics, Inc. vs DaVita)HALO vs UHS (Halozyme Therapeutics, Inc. vs Universal Health Services)HALO vs KYMR (Halozyme Therapeutics, Inc. vs Kymera Therapeutics)HALO vs RGEN (Halozyme Therapeutics, Inc. vs Repligen)HALO vs FMS (Halozyme Therapeutics, Inc. vs Fresenius Medical Care)

All health care companies by market valueLargest companies in the United StatesAll stocks A–Z

Halozyme Therapeutics, Inc. (HALO): questions and answers

What is HALO's P/E ratio?

Halozyme Therapeutics, Inc. trades at 24.0× its last twelve months' earnings and 9.1× next year's expected earnings. At its fiscal year-ends over the past 7 years the P/E ranged from 13.9× to 46.9×, with a median of 26.3×.

What is Halozyme Therapeutics, Inc.'s market cap?

Halozyme Therapeutics, Inc. is valued at $10.96B at a share price of $96.16.

Is HALO overvalued or undervalued?

Against its own history, HALO is above its usual price: the price is 16% above the $83.15 implied by the median multiples it has traded at (price / earnings, price / sales, price / book, price / free cash flow). That compares the stock with its past; it does not say whether the business now deserves a higher or lower multiple.

Is HALO above its 200-week moving average?

Yes. HALO is 66.2% above its 200-week average of $57.85. Long-term investors watch that line because strong companies rarely trade below it for long.

How fast is Halozyme Therapeutics, Inc. growing?

Over the last five fiscal years Halozyme Therapeutics, Inc.'s revenue grew 39.2% a year and its earnings per share 23.0% a year; over ten years revenue grew 26.3% a year.

Does HALO pay a dividend?

Halozyme Therapeutics, Inc. does not currently pay a regular dividend.

Cite this page

Funkfolio, “Halozyme Therapeutics, Inc. (HALO) stock: price, valuation and fundamentals”, data as of 17 November 2026. https://funkfolio.com/stock/HALO

Underlying data: Yahoo Finance; company filings with the SEC.